vs
MAXIMUS, INC.（MMS）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
MAXIMUS, INC.の直近四半期売上が大きい（$1.3B vs $772.1M、Revvityの約1.7倍）。Revvityの純利益率が高く（12.7% vs 7.0%、差は5.8%）。Revvityの前年同期比売上増加率が高い（5.9% vs -4.1%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $-250.7M）。過去8四半期でRevvityの売上複合成長率が高い（9.0% vs -0.1%）
MAXIMUS社は米国の政府向けサービス企業で、米国、カナダ、英国などで事業を展開している。メディケイド、メディケア、医療改革、就労支援、学生ローン管理など各種政府プログラムに管理業務や関連サービスを提供する。本社はバージニア州タイソンズに所在し、従業員数3万9600人、2024会計年度の売上高は53億米ドルである。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
MMS vs RVTY — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.3B | $772.1M |
| 純利益 | $93.9M | $98.4M |
| 粗利率 | 23.7% | — |
| 営業利益率 | 10.9% | 14.5% |
| 純利益率 | 7.0% | 12.7% |
| 売上前年比 | -4.1% | 5.9% |
| 純利益前年比 | 128.0% | 3.9% |
| EPS（希薄化後） | $1.70 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.4B | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.3B | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
| Q4 25 | $93.9M | $98.4M | ||
| Q3 25 | $75.3M | $46.7M | ||
| Q2 25 | $106.0M | $53.9M | ||
| Q1 25 | $96.6M | $42.2M | ||
| Q4 24 | $41.2M | $94.6M | ||
| Q3 24 | $72.5M | $94.4M | ||
| Q2 24 | $89.8M | $55.4M | ||
| Q1 24 | $80.5M | $26.0M |
| Q4 25 | 23.7% | — | ||
| Q3 25 | 25.3% | 53.6% | ||
| Q2 25 | 26.7% | 54.5% | ||
| Q1 25 | 24.9% | 56.5% | ||
| Q4 24 | 21.5% | — | ||
| Q3 24 | 22.9% | 56.3% | ||
| Q2 24 | 25.3% | 55.7% | ||
| Q1 24 | 23.6% | 54.6% |
| Q4 25 | 10.9% | 14.5% | ||
| Q3 25 | 9.3% | 11.7% | ||
| Q2 25 | 12.3% | 12.6% | ||
| Q1 25 | 11.2% | 10.9% | ||
| Q4 24 | 6.2% | 16.3% | ||
| Q3 24 | 8.5% | 14.3% | ||
| Q2 24 | 10.8% | 12.4% | ||
| Q1 24 | 9.5% | 6.8% |
| Q4 25 | 7.0% | 12.7% | ||
| Q3 25 | 5.7% | 6.7% | ||
| Q2 25 | 7.9% | 7.5% | ||
| Q1 25 | 7.1% | 6.4% | ||
| Q4 24 | 2.9% | 13.0% | ||
| Q3 24 | 5.5% | 13.8% | ||
| Q2 24 | 6.8% | 8.0% | ||
| Q1 24 | 6.0% | 4.0% |
| Q4 25 | $1.70 | $0.86 | ||
| Q3 25 | $1.27 | $0.40 | ||
| Q2 25 | $1.86 | $0.46 | ||
| Q1 25 | $1.69 | $0.35 | ||
| Q4 24 | $0.69 | $0.77 | ||
| Q3 24 | $1.18 | $0.77 | ||
| Q2 24 | $1.46 | $0.45 | ||
| Q1 24 | $1.31 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $137.6M | $919.9M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $1.7B | $7.3B |
| 総資産 | $4.2B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $137.6M | $919.9M | ||
| Q3 25 | $222.4M | $931.4M | ||
| Q2 25 | $59.8M | $991.8M | ||
| Q1 25 | $108.1M | $1.1B | ||
| Q4 24 | $72.7M | $1.2B | ||
| Q3 24 | $183.1M | $1.2B | ||
| Q2 24 | $102.8M | $2.0B | ||
| Q1 24 | $77.4M | $1.7B |
| Q4 25 | $1.7B | $7.3B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.8B | $7.6B | ||
| Q1 25 | $1.7B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.8B | $7.9B | ||
| Q2 24 | $1.8B | $7.9B | ||
| Q1 24 | $1.8B | $7.8B |
| Q4 25 | $4.2B | $12.2B | ||
| Q3 25 | $4.1B | $12.1B | ||
| Q2 25 | $4.5B | $12.4B | ||
| Q1 25 | $4.2B | $12.4B | ||
| Q4 24 | $4.1B | $12.4B | ||
| Q3 24 | $4.1B | $12.8B | ||
| Q2 24 | $4.0B | $13.4B | ||
| Q1 24 | $4.0B | $13.4B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $-244.4M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $-250.7M | $161.8M |
| FCFマージンFCF / 売上 | -18.6% | 21.0% |
| 設備投資強度設備投資 / 売上 | 0.5% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | -2.60× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $218.5M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $-244.4M | $182.0M | ||
| Q3 25 | $649.4M | $138.5M | ||
| Q2 25 | $-182.7M | $134.3M | ||
| Q1 25 | $42.7M | $128.2M | ||
| Q4 24 | $-80.0M | $174.2M | ||
| Q3 24 | $163.8M | $147.9M | ||
| Q2 24 | $199.3M | $158.6M | ||
| Q1 24 | $130.5M | $147.6M |
| Q4 25 | $-250.7M | $161.8M | ||
| Q3 25 | $641.8M | $120.0M | ||
| Q2 25 | $-198.2M | $115.5M | ||
| Q1 25 | $25.5M | $112.2M | ||
| Q4 24 | $-103.0M | $149.8M | ||
| Q3 24 | $131.9M | $125.6M | ||
| Q2 24 | $164.6M | $136.6M | ||
| Q1 24 | $105.2M | $129.7M |
| Q4 25 | -18.6% | 21.0% | ||
| Q3 25 | 48.7% | 17.2% | ||
| Q2 25 | -14.7% | 16.0% | ||
| Q1 25 | 1.9% | 16.9% | ||
| Q4 24 | -7.3% | 20.5% | ||
| Q3 24 | 10.0% | 18.4% | ||
| Q2 24 | 12.5% | 19.7% | ||
| Q1 24 | 7.8% | 20.0% |
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 1.3% | 2.4% | ||
| Q4 24 | 1.6% | 3.4% | ||
| Q3 24 | 2.4% | 3.3% | ||
| Q2 24 | 2.6% | 3.2% | ||
| Q1 24 | 1.9% | 2.7% |
| Q4 25 | -2.60× | 1.85× | ||
| Q3 25 | 8.63× | 2.97× | ||
| Q2 25 | -1.72× | 2.49× | ||
| Q1 25 | 0.44× | 3.03× | ||
| Q4 24 | -1.94× | 1.84× | ||
| Q3 24 | 2.26× | 1.57× | ||
| Q2 24 | 2.22× | 2.87× | ||
| Q1 24 | 1.62× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MMS
| Clinical Services | $523.7M | 39% |
| Cost Plus Contracts | $386.4M | 29% |
| Outside The United States | $143.2M | 11% |
| International Government Agencies | $141.0M | 10% |
| Technology Solutions | $74.8M | 6% |
| Employment And Other | $70.2M | 5% |
| Other Including Local Municipalities And Commercial Customers | $17.6M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
